Humanetics Corporation
John Dykstra has a robust leadership background with extensive experience in various executive roles across multiple organizations. Currently, Dykstra serves as a Board Member and Chief Operating Officer at Humanetics Corporation, a position held since April 1998. Previously, Dykstra founded and chaired MetaLogics Corporation from 2008 until September 2021, and served as President at AdvantRX Corporation from January 2000 to December 2008. Earlier in the career, Dykstra held the position of Senior Vice President at Chart Industries from 1991 to 1998, and was Vice President of Marketing and Business Development at Dataserv from 1987 to 1991. Furthermore, Dykstra began the professional journey as a Manager in the Management Consulting Division at KPMG from 1984 to 1987. Dykstra holds a B.S. in Finance from the Indiana University - Kelley School of Business, completed in 1980.
This person is not in the org chart
This person is not in any teams
Humanetics Corporation
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis. BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation. This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury. For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.